VieCure

About VieCure

VieCure is a health technology company, founded in 2015 by Gerry Hogue and Dr. Fred Ashbury, that provides an AI-powered platform for oncology care. The company is headquartered in Greenwood Village, Colorado. The impetus for the company's creation was the growing complexity of cancer care due to the shift towards precision medicine. CEO Michael Power's personal experience with his mother's stage IV lung cancer diagnosis further solidified the mission to equip clinicians with better tools for personalized treatment.

The company’s core offering is the Halo Intelligence™ platform, a digital ecosystem that functions as a clinical decision support system and a purpose-built electronic medical record (EMR) for oncology. This platform integrates patient data, including medical history, genomics, and imaging, with an AI inference engine and a codified library of clinical knowledge to help oncologists create personalized treatment plans. The system is designed to streamline workflows, reduce operational burdens for clinicians, and ensure treatment decisions are evidence-based and up-to-date with the latest in precision medicine. The ecosystem also includes mobile applications for both physicians and patients, telehealth capabilities, and a data analytics environment.

VieCure primarily serves community oncology clinics, which manage over 80% of cancer patients in the United States. Its business model involves partnering with these cancer centers and networks to implement the Halo platform, aiming to standardize and improve the quality of care, particularly in value-based care models. VieCure has established partnerships with organizations like the American Oncology Network, Oncology Care Partners, and Guardant Health to integrate genomic testing directly into the clinical workflow. The company has demonstrated significant funding success, raising a total of $113 million over several rounds, including a $43 million round in January 2026 led by Mitch Rales and Northpond Ventures. This capital is being used to expand its AI platform and increase its footprint across community oncology practices, where it manages care for nearly 30,000 patients.